Chain-Driven Frontier Nuclear Medicine Innovation | Nanolattix Chairman Qu Zhican Attends BIOCHINA 2026
Release time:
2026-03-16
From March 12 to 14, 2026, BIOCHINA 2026 (the 11th) was grandly held at the Suzhou International Expo Center. The event gathered numerous top experts, scholars, and industry leaders for in-depth discussions on core topics including drug R&D, clinical translation, and global布局. Dr. Qu Zhican, Chairman of Nanolattix, was invited to attend and shared key insights at two major forums.
On March 13, during the roundtable dialogue titled "Innovative Transformation Pathways and Global Industrial Layout of Nuclear Medicine R&D," Dr. Qu Zhican engaged in discussions with industry experts including Li Jianguo, Party Secretary of the Institute of Radiation Medicine at the China Institute for Radiation Protection, and Yuan Daxing, General Manager of Quark Pharmaceuticals. The panel focused on transcending traditional target limitations, developing emerging targets, and deeply analyzed the multidimensional challenges within the globalization process of nuclear medicine, jointly deliberating on cutting-edge paths for nuclear medicine innovation and development.
On March 14, Dr. Qu Zhican delivered a keynote speech titled "From Technological Innovation Platforms to the Synergistic Development of RDC and ADC in Nuclear Medicine" at the "XDC Technology Innovation and Clinical Development" forum. In her presentation, she systematically outlined the advancements in Nanolattix's BioLattix technology platform within the field of conjugate drugs, with a particular focus on the innovative pathway for the synergistic development of RDC and ADC. Drawing on Nanolattix's R&D practices with innovative drugs such as T320-ADC and RT01-RDC, Dr. Qu shared forward-looking perspectives on novel target discovery and clinical medicine, highlighting the company's systematic approach in drug design, target screening, and clinical translation.
Through this exhibition, Nanolattix not only showcased its technological accumulation and strategic planning in the fields of nuclear medicine and antibody-drug conjugates but also established deep connections with partners across the industry chain. In the future, Nanolattix will continue to deeply cultivate innovation in nuclear medicine, adopting an open and collaborative attitude to work alongside industry peers, providing patients with more precise and effective treatment options, and contributing wisdom and solutions to the development of the biomedical industry.
Tag:
recommend News
Share
